Key Stats for Zoetis Stock
- Past-Week Performance: +1.8%
- 52-Week Range: $115.3 to $177
- Current Price: $125.9
What Happened?
Zoetis stock (ZTS) trading at $125.93, nearly 29% below its 52-week high of $177.00, understates a company that just beat Q4 revenue estimates by $27 million while simultaneously acquiring Neogen’s genomics business on March 2.
Leerink Partners analyst Daniel Clark flagged that Simparica, dermatology, and OA pain franchises came in lighter than expected, yet Zoetis still delivered Q4 adjusted EPS of $1.48 against a $1.40 estimate.
Underneath the headline miss narrative, the Simparica franchise alone generated $1.5 billion in 2025 revenue growing 12% operationally, with Simparica Trio crossing $1 billion in U.S. annual sales for the first time.
Kristin Peck, Chief Executive Officer, stated on the Q4 earnings call that “this is not a decline in underlying demand for care, but rather greater price sensitivity and tighter household budgets,” directly relevant as Merck’s Numelvi received U.S. FDA approval on February 25 intensifying dermatology competition.
With CYTOPOINT long-acting approval expected late 2026, Lenivia launching in EU and Canada in the first half of 2026, and 12 potential blockbusters in development, Zoetis is building a pipeline that extends its competitive lead well beyond current franchise pressure.
Wall Street’s Take on ZTS Stock
The March 2 Neogen genomics acquisition for $160 million directly extends Zoetis’s precision animal health capabilities, reinforcing the 4.7% revenue growth consensus analysts already expect for 2026.
Fundamentally, revenue grows from $9.5 billion in 2025 to a projected $9.9 billion in 2026, while normalized EPS accelerates 9.6% to $7.0, signaling a business stabilizing after a turbulent year.
Wall Street currently shows 7 buys, 4 outperforms, and 9 holds against a mean price target of $151.0, implying 19.9% upside from $125.9, though the growing hold count reflects fatigue around U.S. companion animal softness.
The analyst target range spans $130.0 on the low end to $190.0 on the high, with the upside scenario hinging on CYTOPOINT long-acting approval expected late 2026 and the low end reflecting sustained Librela U.S. decline after a 32% drop in Q4.
What Does the Valuation Model Say?
The TIKR valuation model targets $178.4 by December 31, 2030, implying 41.7% total return and a 7.5% IRR annually from today’s $125.9. That gap exists despite a business generating $4.2 billion in EBITDA in 2025 at 44.8% margins.
The market prices ZTS as a dermatology story in decline, ignoring that Simparica Trio crossed $1 billion in U.S. annual sales while livestock delivered 8% organic operational growth in 2025.
EBITDA margins held at 44.8% in 2025 despite competitive pressure and consumer softness, a level of structural profitability the current price does not reflect.
Meanwhile, CFO Wetteny Joseph told the Bank of America Animal Health Summit on February 26 that Zoetis sees “a disconnect between that and where we’re valued today,” signaling management conviction that the stock is mispriced.
However, Librela’s 32% U.S. decline in Q4 remains the single biggest threat; if that weakness spreads to the broader OA pain franchise, the pipeline reacceleration thesis breaks down entirely
The CYTOPOINT long-acting U.S. approval expected late 2026 will serve as the clearest signal of whether Zoetis can offset dermatology competition with next-generation portfolio momentum.
ZTS is undervalued at $125.9 relative to its $178.4 model target, and the CYTOPOINT approval timeline is the single variable that determines whether that gap closes.
Should You Invest in Zoetis Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ZTS stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Zoetis Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ZTS stock on TIKR for Free →
